Mainz Biomed’s (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
By Johnny Rice, Benzinga Mainz Biomed (NASDAQ: MYNZ) has taken a significant step forward in the fight against colorectal cancer with its application to the FDA for breakthrough device designation for its colorectal cancer test. This innovative screening test could revolutionize how we detect one of the most prevalent and deadly cancers worldwide. At its […]
Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers
By Anthony Termini, Benzinga According to Cancer Research UK, “Cancer survival has doubled in the last 40 years, but progress hasn’t been equal across all types of the disease.” Their research shows that survival rates of some forms of brain tumors and pancreatic cancers have barely improved in that time. One company has made it […]
